Clinical trialNCT03147287Active, not recruitingPhase 2Interventional

Palbociclib After CDK and Endocrine Therapy (PACE)

SponsorDana-Farber Cancer InstituteEnrollment220Metastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Erica L Mayer, MD MPH
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Miami
Miami, Florida, United States
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
the University of Kansas Cancer Center - North
Kansas City, Kansas, United States
the University of Kansas Cancer Center - Overland Park
Overland Park, Kansas, United States
the University of Kansas Cancer Center
Westwood, Kansas, United States
University of Louisville
Louisville, Kentucky, United States
Eastern Maine Medical Center
Bangor, Maine, United States
Boston Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber at St. Elizabeth'S Medical Center
Brighton, Massachusetts, United States
Df/bwcc at Milford Regional Medical Center
Milford, Massachusetts, United States
Df/bwcc in Clinical Affiliation With South Shore Hospital
South Weymouth, Massachusetts, United States
the University of Kansas Cancer Center - Lee'S Summit
Lee's Summit, Missouri, United States
Washington University
St Louis, Missouri, United States
Dana-Farber/new Hampshire Oncology-Hematology
Londonderry, New Hampshire, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor University
Houston, Texas, United States
Aurora Cancer Care
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Avelumab →Fulvestrant →Palbociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Sept 2017
Primary completion: 31 Dec 2022
Completion: 30 Jun 2026
Last update posted: 30 Sept 2025
Registered enrollment: 220
Registry id: NCT03147287

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.